Table 2 Effect of interventions on primary and secondary endpoints
End Point | Monotherapy (n = 79) | Combination therapy (n = 60) | P-value# |
|---|---|---|---|
Clinical success on Day 10, no. (%) | 48 (60.7) | 36 (60) | 1 |
Clinical success on Day 20, no. (%) | 70(88.6) | 53 (88.3) | 1 |
FEV1, L | |||
FEV1 on Day 1 | 0.75 ± 0.19 | 0.73 ± 0.21 | 0.22 |
ΔFEV1 on Day 10 | 0.17 ± 0.21 | 0.20 ± 0.26 | 0.24 |
ΔFEV1 on Day 20 | 0.18 ± 0.28 | 0.24 ± 0.25 | 0.56 |
VAS score | |||
ΔVAS score on Day 10 | − 10.6 ± 9.6 | − 10.5 ± 13.3 | 0.92 |
ΔVAS score on Day 20 | − 21.3 ± 15.1 | − 23.8 ± 17.6 | 0.26 |
CRP (mg/L) | |||
ΔCRP on Day 10 | − 13.5 ± 14.3 | − 12.6 ± 16.1 | 0.099 |
ΔCRP on Day 20 | − 22.1 ± 14.5 | − 26.9 ± 15.7 | 0.004 |